Bilateral RRM confers a substantial reduction in breast cancer risk for unaffected individuals with PVs in BRCA1–2 genes, estimated at 90% and up to 95% when combined with RRSO [45,46,47,48]. Here, BRCA1 is linked to breast carcinoma.